Proteasome Substrate III Fluorogenic

CAT:
952-B2014186
Size:
2.5 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Proteasome Substrate III Fluorogenic - image 1

Proteasome Substrate III Fluorogenic

  • Description:

    Proteasome Substrate III Fluorogenic_x000D_ Catalog number: B2014186_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 2.5 mg_x000D_ Molecular Weight or Concentration: 763.8 g/mol_x000D_ Supplied as: Powder_x000D_ Applications: molecular tool for various biochemical applications_x000D_ Storage: -20°C_x000D_ Keywords: Proteasome Substrate III, Fluorogenic, Suc-LLVY-AMC, Chymotrypsin Substrate III, Fluorogenic_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Nehybov T, marda J, Daniel L, Stiborek M, Kanick_ V, Spasojevi I, Preisler J, Damborsk_ J, Bene P. Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells Int J Mol Sci. 2017 Mar 29;18(4):729._x000D_ 2: Morales P, Kong M, Pizarro E, Pasten C. Participation of the sperm proteasome in human fertilization Hum Reprod. 2003 May;18(5):1010-7._x000D_ 3: Sixt SU, Costabel U, Bonella F, Grunert K, Alami R, Hakenbeck J, Bauer P, Dahlmann B, Schmid KW, Peters J, Wohlschlaeger J. Alveolar and intraparenchymal proteasome in sarcoidosis Respir Med. 2014 Oct;108(10):1534-41._x000D_ 4: Gohlke S, Kloss A, Tsokos M, Textoris-Taube K, Keller C, Kloetzel PM, Dahlmann B. Adult human liver contains intermediate-type proteasomes with different enzymatic properties Ann Hepatol. 2014 Jul-Aug;13(4):429-38._x000D_ 5: Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, van Hees HW, Dekhuijzen PN. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease Am J Respir Crit Care Med. 2006 Nov 1;174(9):997-1002._x000D_ 6: Dahlmann B, Ruppert T, Kloetzel PM, Kuehn L. Subtypes of 20S proteasomes from skeletal muscle Biochimie. 2001 Mar-Apr;83(3-4):295-9._x000D_ 7: Baldovino S, Piccinini M, Anselmino A, Ramondetti C, Rinaudo MT, Costanzo P, Sena LM, Roccatello D. Structural and functional properties of proteasomes purified from the human kidney J Nephrol. 2006 Nov-Dec;19(6):710-6._x000D_ 8: Hassan SB, Lvborg H, Lindhagen E, Karlsson MO, Larsson R. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome Anticancer Res. 2006 Nov-Dec;26(6B):4431-6._x000D_ 9: Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia Clin Cancer Res. 2003 Oct 1;9(12):4570-7._x000D_ 10: Bokkala S, Rubin E, Joseph SK. Effect of chronic ethanol exposure on inositol trisphosphate receptors in WB rat liver epithelial cells Alcohol Clin Exp Res. 1999 Dec;23(12):1875-83._x000D_ _x000D_ Products Related to Proteasome Substrate III Fluorogenic can be found at Substrates
  • Short Description:

    Catalog Number: B2014186 (2.5 mg)
  • Weight:

    0.15
  • Length:

    2
  • Width:

    0.5
  • Height:

    0.5